Septerna Advances Lead Programs SEP-479 and SEP-631, Reports Strong Cash Runway into 2029

summarizeSummary

Septerna provided positive updates on its lead clinical programs, SEP-479 and SEP-631, and announced a strong cash runway extending into 2029, bolstering its financial stability and pipeline progression.

check_boxKey Events

• SEP-479 Phase 1 Initiation

  The company anticipates initiating a Phase 1 clinical trial for SEP-479, an oral PTH1R agonist for hypoparathyroidism, in the first half of 2026. Preclinical studies showed no hyperbilirubinemia, addressing a prior safety concern from a discontinued candidate.

• SEP-631 Phase 1 Data Anticipated

  Topline results from the Phase 1 SAD/MAD trial for SEP-631, an MRGPRX2 NAM for mast cell-driven diseases, are expected to be presented at the AAAAI Annual Meeting in March 2026.

• Extended Cash Runway

  Septerna projects its cash runway will support operating plans at least into 2029, providing significant financial stability for its ongoing research and development.

• Novo Nordisk Collaboration Update

  The company reiterated details of its collaboration with Novo Nordisk for metabolic diseases, including a $195 million upfront payment received in July 2025 and potential milestones of approximately $500 million per program.

auto_awesomeAnalysis

Septerna's presentation at the J.P. Morgan Healthcare Conference highlights significant progress in its lead pipeline assets and a robust financial position. The planned initiation of a Phase 1 trial for SEP-479, a PTH1R agonist for hypoparathyroidism, is a key milestone, especially with preclinical studies showing no hyperbilirubinemia, addressing a prior issue with a discontinued candidate. The anticipated topline data for SEP-631 in March 2026 provides a near-term catalyst for the MRGPRX2 NAM program. Furthermore, the extended cash runway into 2029 significantly de-risks the company's operations, providing ample time to advance its pipeline, including the collaboration with Novo Nordisk.